The company's drug candidates target galectin proteins, which are key mediators of biologic and pathologic function, and they focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Their strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources. They are pursuing a clear development pathway to clinical enhancement and commercialization for their lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer.